Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form
- PMID: 34420300
- PMCID: PMC8424683
- DOI: 10.1021/acs.molpharmaceut.1c00485
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form
Abstract
In this study, the phase diagram of the ternary system of ezetimibe-simvastatin-fenofibrate was established. It has been proven that the ternary composition recommended for the treatment of mixed hyperlipidemia forms a eutectic system. Since eutectic mixtures are characterized by greater solubility and dissolution rate, the obtained result can explain the marvelous medical effectiveness of combined therapy. Considering that another well-known method for improving the aqueous solubility is amorphization, the ternary system with eutectic concentration was converted into an amorphous form. Thermal properties, molecular dynamics, and physical stability of the obtained amorphous system were thoroughly investigated through various experimental techniques compared to both: neat amorphous active pharmaceutical ingredients (considered separately) and other representative concentrations of ternary mixture. The obtained results open up a new way of selecting the therapeutic concentrations for combined therapies, a path that considers one additional variable: eutecticity.
Keywords: amorphous pharmaceuticals; eutectic system; ezetimibe; fenofibrate; physical stability; simvastatin; ternary eutectic.
Conflict of interest statement
The authors declare no competing financial interest.
Figures











References
-
- Farnier M. Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. Clin. Med. Ther. 2009, 1, 2036.10.4137/cmt.s2036. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical